Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Grifols
- 18 May 2022 Results assessing comparative clinical efficacy and cost-effectiveness in patients with myasthenia gravis using data from three clinical studies: ADAPT, REGAIN and GTI1408 presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 21 Feb 2018 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Status changed from recruiting to active, no longer recruiting.